These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 11156342)

  • 1. Transforming growth factor-beta1 as a surrogate marker of hepatic dysfunction in chronic liver diseases.
    Flisiak R; Prokopowicz D
    Clin Chem Lab Med; 2000 Nov; 38(11):1129-31. PubMed ID: 11156342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis.
    Flisiak R; Pytel-Krolczuk B; Prokopowicz D
    Cytokine; 2000 Jun; 12(6):677-81. PubMed ID: 10843744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming growth factor-beta1 in plasma and liver of children with liver disease.
    Rosensweig JN; Omori M; Page K; Potter CJ; Perlman EJ; Thorgeirsson SS; Schwarz KB
    Pediatr Res; 1998 Sep; 44(3):402-9. PubMed ID: 9727721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma transforming growth factor beta1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B.
    Flisiak R; Jaroszewicz J; Lapiński TW; Flisiak I; Rogalska M; Prokopowicz D
    Regul Pept; 2005 Nov; 131(1-3):54-8. PubMed ID: 16081167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1.
    Wiercińska-Drapało A; Flisiak R; Prokopowicz D
    Cytokine; 2001 Jun; 14(6):343-6. PubMed ID: 11497495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels and hepatic mRNA expression of transforming growth factor-beta1 in patients with fulminant hepatic failure.
    Miwa Y; Harrison PM; Farzaneh F; Langley PG; Williams R; Hughes RD
    J Hepatol; 1997 Nov; 27(5):780-8. PubMed ID: 9382963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentration of transforming growth factor (TGF)-beta 1 does not predict advanced liver fibrosis in children with chronic hepatitis B.
    Lebensztejn DM; Sobaniec-Lotowska M; Kaczmarski M; Werpachowska I; Sienkiewicz J
    Hepatogastroenterology; 2004; 51(55):229-33. PubMed ID: 15011870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum transforming growth factor-beta1(TGF-beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C [corrected].
    Kirmaz C; Terzioglu E; Topalak O; Bayrak P; Yilmaz O; Ersoz G; Sebik F
    Eur Cytokine Netw; 2004; 15(2):112-6. PubMed ID: 15319169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced plasma transforming growth factor-beta1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis.
    Tsushima H; Kawata S; Tamura S; Ito N; Shirai Y; Kiso S; Doi Y; Yamada A; Oshikawa O; Matsuzawa Y
    J Hepatol; 1999 Jan; 30(1):1-7. PubMed ID: 9927144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of transforming growth factor beta1 (TGF-beta1) in the pathogenesis and clinical course of chronic hepatitis in children].
    Liberek A; Marek A; Kmieć Z; Kartanowicz D; Szlagatys-Sidorkiewicz A; Łuczak G; Wierzbicki PM; Stanisławowski M; Wierzbicki M; Marek K; Liberek T; Sikorska-Wiśniewska G; Góra-Gebka M; Wegrzyn G; Kamińska B
    Med Wieku Rozwoj; 2009; 13(3):163-70. PubMed ID: 20081261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1--possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis.
    Flisiak R; Maxwell P; Prokopowicz D; Timms PM; Panasiuk A
    Hepatogastroenterology; 2002; 49(47):1369-72. PubMed ID: 12239944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.
    Ben-Ari Z; Pappo O; Druzd T; Sulkes J; Klein T; Samra Z; Gadba R; Tambur AR; Tur-Kaspa R; Mor E
    Cytokine; 2004 Jul; 27(1):7-14. PubMed ID: 15207246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney volume and plasma hepatocyte growth factor-transforming growth factor beta1 ratio among children with biliary atresia before and after liver transplantation: the reversibility of nephromegaly.
    Cheng CH; Tsau YK; Tsai IJ
    Am J Kidney Dis; 2005 Nov; 46(5):830-6. PubMed ID: 16253722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma.
    Okumoto K; Hattori E; Tamura K; Kiso S; Watanabe H; Saito K; Saito T; Togashi H; Kawata S
    Liver Int; 2004 Feb; 24(1):21-8. PubMed ID: 15101997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary transforming growth factor beta1 levels in hepatitis C virus-related chronic liver disease: correlation between high levels and severity of disease.
    Tsai JF; Jeng JE; Chuang LY; Chang WY; Tsai JH
    Hepatology; 1997 May; 25(5):1141-6. PubMed ID: 9141431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of polymorphism of transforming growth factor beta1 gene on HBV-induced liver cirrhosis].
    Yang ZX; Wang H; Gao CF; Xu LL; Zhao WJ
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1021-6. PubMed ID: 16029542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis.
    Sakaguchi K; Kitano M; Nishimura M; Senoh T; Ohta T; Terao M; Shinji N; Koide N; Tsuji T
    Hepatogastroenterology; 2004; 51(60):1780-3. PubMed ID: 15532825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine excretion of transforming growth factor-beta1 in chronic allograft nephropathy.
    Boratyńska M
    Ann Transplant; 1999; 4(2):23-8. PubMed ID: 10850587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients.
    Stefoni S; Cianciolo G; Donati G; Dormi A; Silvestri MG; Colì L; De Pascalis A; Iannelli S
    Kidney Int; 2002 Jan; 61(1):324-35. PubMed ID: 11786115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer.
    Narai S; Watanabe M; Hasegawa H; Nishibori H; Endo T; Kubota T; Kitajima M
    Int J Cancer; 2002 Feb; 97(4):508-11. PubMed ID: 11802214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.